U.S. Markets closed

GlaxoSmithKline acquires Okairos for $325M

GlaxoSmithKline announced that it has acquired Okairos, a specialist developer of vaccine platform technologies, for $325M in cash. Swiss-based Okairos, a private company, has developed a novel vaccine platform technology which is expected to play an important role in GSK’s development of new prophylactic vaccines, designed to prevent infection as well as new classes of therapeutic vaccines designed to treat infection or disease, the company said.